GLP-1 Drug Market Research Report: Size, Share, Trend Analysis By Drug Type (Short-acting, Long-acting, Dual-action), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Indication (Type 2 Diabetes, Obesity, Cardiovascular Diseases), By Administration Route (Subcutaneous Injection, Oral, Inhalation) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035 ID: MRFR/HC/20411-HCR 128 Pages Last Updated: May 15, 2026 GLP-1 Drug Market Market Size Forecast Period2025 - 2035 CAGR (2025 - 2035)13.17% 2024 Market Size$ 10.77 Billion 2025 Market Size$ 12.19 Billion 2035 Market Size$ 42 Billion Key Players Companies such as Novo Nordisk Eli Lilly Sanofi Boehringer Ingelheim AstraZeneca Merck & Co
Instead, its absorbed directly into the capillaries and enters systemic circulation
GLP-1 analogs and DPP-4 inhibitors in type 2 diabetes therapy: Review of head-to-Head clinical trials
Ozempic Delays Gastric Emptying GLP-1 slows down gastric emptying, the process by which food moves from the stomach to the intestine
[DOI] [PMC free article] [PubMed] [Google Scholar] 107.Zhao X., Petrashen A.P., Sanders J.A., Peterson A.L., Sedivy J.M
